- Home
- IBIO vs KLRS Comparison
IBIO vs KLRS Comparison
Compare IBIO & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | KLRS |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 92.8M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBIO | KLRS |
|---|---|---|
| Price | $1.31 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.75 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 672.6K | 43.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.71 | 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $3.03 |
| 52 Week High | $3.82 | $11.88 |
Technical Indicators
Market Signals| Indicator | IBIO | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 47.07 |
| Support Level | $0.98 | $3.92 |
| Resistance Level | $1.52 | $4.37 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.27 | 30.00 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.